Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433271 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL614515 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL27419562 | 0.94 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL16289367 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15083313 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12405615 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13950543 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8070420 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13652724 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL11934305 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024052550-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335462-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4308551-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2024-01-24 | — | — | EP | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-116981658-A | Novel contrast agents for magnetic resonance imaging | 拜耳股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2011100402-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| EP-2285785-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-5665598-A | Synthesis of chiral N-protected-α-substituted-glycine free acids by zinc-mediated addition of organic halide to glycine cation equivalent | G. D. SEARLE & CO. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5508466-A | REACTING MIXTURE OF N-PROTECTED-ALPHA-SUBSTITUTED-GLYCINE CATION DERIVATIVE AND ELEMENTAL ZINC WITH ORGANIC HALIDE IN POLAR SOLVENT | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | MAG, GBA1, GLRX3 | SMN1; SMN2 777/4885CTSK 2928/4885NFKB1 2510/4885 |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | SMN1; SMN2 2305/4885CTSK 1944/4885NFKB1 3742/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | SMN1; SMN2 3007/4885CTSK 170/4885NFKB1 998/4885 |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | CFTR, SCN5A, SCNN1B | SMN1; SMN2 2347/4885CTSK 4264/4885NFKB1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.